| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
A2058 and HT 1080 tumor cell invasion is 60–80% lessened by peptide 74 (30 μM)[1]. Peptide 74 (30 μM) did not block chemotaxis, cause cytotoxicity, or change the quantity of HT1080 and A2058 human tumor cells [1].
|
|---|---|
| References |
|
| Molecular Formula |
C62H107N23O20S2
|
|---|---|
| Molecular Weight |
1558.78508
|
| Exact Mass |
1557.75
|
| CAS # |
132116-39-3
|
| PubChem CID |
164323
|
| Appearance |
White to off-white solid powder
|
| LogP |
-14
|
| Hydrogen Bond Donor Count |
23
|
| Hydrogen Bond Acceptor Count |
26
|
| Rotatable Bond Count |
49
|
| Heavy Atom Count |
107
|
| Complexity |
3200
|
| Defined Atom Stereocenter Count |
14
|
| SMILES |
N/C(=N/CCC[C@@H](C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)O)CC(=O)N)=O)C)=O)C(C)C)=O)CC(=O)O)=O)=O)CC(=O)N)=O)=O)CS)=O)CCC/N=C(\N)/N)=O)=O)CCCCN)=O)NC([C@@H](NC([C@H]([C@H](O)C)N)=O)CCSC)=O)/N
|
| InChi Key |
DAZBILQQVFBVPE-XKKUQSFHSA-N
|
| InChi Code |
InChI=1S/C62H107N23O20S2/c1-29(2)47(57(101)74-30(3)48(92)81-38(60(104)105)25-43(65)88)83-53(97)36(26-45(90)91)80-55(99)41-16-11-22-85(41)59(103)37(24-42(64)87)75-44(89)27-73-49(93)39(28-106)82-51(95)33(14-9-20-72-62(69)70)77-54(98)40-15-10-21-84(40)58(102)35(12-6-7-18-63)79-50(94)32(13-8-19-71-61(67)68)76-52(96)34(17-23-107-5)78-56(100)46(66)31(4)86/h29-41,46-47,86,106H,6-28,63,66H2,1-5H3,(H2,64,87)(H2,65,88)(H,73,93)(H,74,101)(H,75,89)(H,76,96)(H,77,98)(H,78,100)(H,79,94)(H,80,99)(H,81,92)(H,82,95)(H,83,97)(H,90,91)(H,104,105)(H4,67,68,71)(H4,69,70,72)/t30-,31+,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,46-,47-/m0/s1
|
| Chemical Name |
(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~64.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (64.15 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6415 mL | 3.2076 mL | 6.4152 mL | |
| 5 mM | 0.1283 mL | 0.6415 mL | 1.2830 mL | |
| 10 mM | 0.0642 mL | 0.3208 mL | 0.6415 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04546841 | Completed | Biological: multipeptide cocktail | COVID-19 Vaccine | University Hospital Tuebingen | 2020-11-27 | Phase 1 |
| NCT01069653 | Completed | Biological: HLA-A*2402-restricted CDCA1 and KIF20A peptides | Small Cell Lung Cancer | Shiga University | 2010-02 | Phase 1 |
| NCT06015841 | Recruiting | Biological: Placebo Biological: ACI-7104.056 at Dose A Biological: ACI-7104.056 at Dose B (optional) Biological: ACI-7104.056 at Dose C (optional) |
Parkinson Disease Parkinson Disease 6, Early-Onset |
AC Immune SA | 2023-07-24 | Phase 2 |
| NCT05492500 | Recruiting | Drug: Main cohort (Cohort A): Ponsegromab low dose Drug: Main cohort (Cohort A): Ponsegromab medium dose Drug: Main cohort (Cohort A): ponsegromab high dose |
Heart Failure | Pfizer | 2022-09-26 | Phase 2 |
| NCT06412952 | Recruiting | Drug: 68Ga-RM26 | Glioma | Peking Union Medical College Hospital | 2022-10-01 | Early Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
